Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Arvinas Holding Company ( (ARVN) ) is now available.
On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.
The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’ overall stock score is primarily influenced by its financial challenges, including negative profitability and cash flows. While technical indicators suggest a potential rebound, the stock’s valuation remains unattractive. Positive corporate events and earnings call highlights provide some optimism, but the financial performance remains a significant concern.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform. The company aims to treat debilitating and life-threatening diseases and is currently advancing several investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin Lymphoma, ARV-102 for neurodegenerative disorders, and ARV-806 for mutated cancers.
Average Trading Volume: 2,077,965
Technical Sentiment Signal: Sell
Current Market Cap: $469.3M
For an in-depth examination of ARVN stock, go to TipRanks’ Overview page.